Internal Medicine Doctors in Centerport, NY Accepting Medicare

2 Internal Medicine doctors found. Showing 1 - 2

Dr. Sunita Mohan Makhijani, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 12 Little Neck Rd, Centerport, NY 11721 Phone: 516-242-8327    Fax: 631-757-2097

Ralph Fenderson, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 41 Spring Hollow Rd, Centerport, NY 11721 Phone: 631-757-9685    Fax: 631-757-9685

News Archive

Bristol-Myers Squibb to acquire Amylin

Bristol-Myers Squibb Company and Amylin Pharmaceuticals, Inc. announced today that Bristol-Myers Squibb will acquire Amylin for $31.00 per share in cash, pursuant to a cash tender offer and second step merger, or an aggregate purchase price of approximately $5.3 billion.

Lead 8A analog can treat osteosarcoma in children

Jiayuh Lin, PhD, and colleagues at Nationwide Children's Hospital have developed a drug to target the most common cancerous bone tumor in children, osteosarcoma, using a version of the FDA-approved drug, Celebrex. The team will soon begin testing the drug using human and canine tumor cell lines thanks to a two-year, $200,000 grant from Alex's Lemonade Stand Foundation for Childhood Cancer.

Viewpoints: Health law can be intensely personal; Insurers' promises miss the mark

Whenever I read or hear objections to "Obamacare," I think about my friend's son. The son had cancer when he was a teenager. Thankfully, his dad had health insurance - through his job. A job that he lost. He has a new job now, but like so many new jobs, it doesn't pay as much - and it doesn't come with benefits. Fortunately, his son seems to have beaten the cancer. And the family now has health insurance from the mom's job. So the son, thanks to "Obamacare," can be insured through his parents.

First Edition: October 10, 2013

Today's headlines include a new Associated Press poll that offers the public's early reviews of the first days of the health law's online insurance marketplaces.

ADHD drug market will decrease from $5 billion in 2009 to $4.1 billion in 2019: Report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the attention-deficit/hyperactivity disorder (ADHD) drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan will fluctuate modestly over the next decade, decreasing from $5 billion in 2009 to a trough in 2013 before climbing to $4.1 billion in 2019.

Read more Medical News

› Verified 2 days ago